Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics 'getting more confident' as it hits half-way point in human studies

Dr Cath O'Neill, chief executive of SkinBioTherapeutics PLC (AIM:SBTX), tells Proactive London's Andrew Scott there've been no safety or compliance concerns with people taking part in a test of the company’s skin cream.

Half the 120 volunteers have been through the trial process with the study set to complete as expected during this quarter.

Data yielded will be assessed to determine the effectiveness of the group’s SkinBiotix technology and whether it retains the same beneficial property of improving skin health when in a cream formulation.

Meet Faron Pharmaceuticals Ltd, Belvoir Lettings, Silence Therapeutics PLC, ANGLE PLC and ReNeuron Group PLC at our event, London , 23 May 2019. Register here »
View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use